Disease Domain | Count |
---|---|
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
AAV based gene therapy | 1 |
Small molecule drug | 1 |
Top 5 Target | Count |
---|---|
TEAD x YAP1 | 1 |
Target |
Mechanism TEAD inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Gene transference |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CFTR gene modulators |
Active Org.- |
Originator Org. ReCode Therapeutics, Inc.Startup |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Nov 2024 |
Sponsor / Collaborator |
Start Date14 Oct 2024 |
Sponsor / Collaborator |
Start Date01 Oct 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
CPD3.1 ( TEAD x YAP1 ) | Neoplasms More | Preclinical |
Aquaporin-1 CRISPR/Cas9 gene therapy (University of Bristol/UCL Institute of Ophthalmology/University of Cambridge) | Glaucoma More | Preclinical |
HF-1020 | Inflammation More | Pending |
Adeno-associated viral vector delivered nerve growth factor gene therapy (University of Bristol) | Heart Failure More | Pending |
[3H]BU-97001 ( δ opioid receptor ) | Central Nervous System Diseases More | Pending |